Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

Front Oncol. 2023 Nov 27:13:1333273. doi: 10.3389/fonc.2023.1333273. eCollection 2023.

Authors

Ema Mosleh¹, Stacy Snyder¹, Ningying Wu², Daniel N Willis¹, Rema Malone³, Robert J Hayashi¹

Affiliations

¹ Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
² Biostatistics Shared Resource, Division of Public Health Sciences and Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.
³ Division of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St. Louis, MO, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2023.1280587.].

Keywords: AYA; HDMTX; adverse effect; delayed clearance; methotrexate; nephrotoxicity; pediatric cancer; supportive care.

Copyright © 2023 Mosleh, Snyder, Wu, Willis, Malone and Hayashi.

Publication types

Published Erratum